Education
About Us
Working with TipRanks
Follow Us
Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
RESEARCH TOOLSreports
Total Valuation
Qyuns Therapeutics Co., Ltd. Class H has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Qyuns Therapeutics Co., Ltd. Class H has 222,071,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding222,071,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Qyuns Therapeutics Co., Ltd. Class H’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee43.51K
Profits Per Employee-1.54M
Employee Count339
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Qyuns Therapeutics Co., Ltd. Class H is ―. Qyuns Therapeutics Co., Ltd. Class H’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Qyuns Therapeutics Co., Ltd. Class H had revenue of 14.75M and earned -507.75M in profits. Earnings per share was -2.47.
Revenue14.75M
Gross Profit14.75M
Operating Income-504.51M
Pretax Income-521.33M
Net Income-507.75M
EBITDA-484.12M
Earnings Per Share (EPS)-2.47
Cash Flow
In the last 12 months, operating cash flow was -199.16M and capital expenditures -3.91M, giving a free cash flow of -203.06M billion.
Operating Cash Flow-199.16M
Free Cash Flow-203.06M
Free Cash Flow per Share-0.91
Dividends & Yields
Qyuns Therapeutics Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.48
52-Week Price Change-20.93%
50-Day Moving Average12.50
200-Day Moving Average12.16
Relative Strength Index (RSI)60.91
Average Volume (3m)243.11K
Important Dates
Qyuns Therapeutics Co., Ltd. Class H upcoming earnings date is Mar 28, 2025, Before Open (Confirmed).
Last Earnings DateAug 15, 2024
Next Earnings DateMar 28, 2025
Ex-Dividend Date―
Financial Position
Qyuns Therapeutics Co., Ltd. Class H as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Qyuns Therapeutics Co., Ltd. Class H has paid -73.00K in taxes.
Income Tax-73.00K
Effective Tax Rate―
Enterprise Valuation
Qyuns Therapeutics Co., Ltd. Class H EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Qyuns Therapeutics Co., Ltd. Class H has HK$629.63M in cash and marketable securities with ¥500.93M in debt, giving a net cash position of -HK$128.70M billion.
Cash & Marketable SecuritiesHK$629.63M
Total Debt¥500.93M
Net Cash-HK$128.70M
Net Cash Per Share-HK$0.58
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Qyuns Therapeutics Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―